PriMera Scientific Surgical Research and Practice (ISSN: 2836-0028)

Review Article

Volume 4 Issue 3

Integrative Approaches to Treating Patients with Lung Cancer and Side Effects of Traditional Treatment in Lung Cancer

Christina Rahm*

August 16, 2024

DOI : 10.56831/PSSRP-04-126

View PDF

Abstract

Cancer treatment is a difficult task. Mental and bodily exhaustion are possible outcomes of the practice. Alternative therapy options for cancer may be enhanced via integrative cancer care. Combining traditional medicine with complementary and alternative medicine, nutritional medicine, and lifestyle interventions to cure and prevent disease and optimize health is an integrated approach to treating illnesses like lung cancer. The case study has also explored some challenges patients face in this lung cancer treatment journey. The patient, after being diagnosed with Stage IV non-small cell lung cancer NSCLC adenocarcinoma, undergoes a set of combination of carboplatin-pemetrexed-pembrolizumab chemotherapy, which exposes her to a significant number of side effects like extreme weakness, elevated inflammatory markers, and nausea. Throughout this paper, we will discuss the integrative approaches to treating patients with lung cancer and the side effects of traditional treatment in lung cancer.

References

  1. Avancini A., et al. “Physical activity and exercise in lung cancer care: will promises be fulfilled?”. The oncologist 25.3 (2020): e555-e569.
  2. Bade BC and Cruz CSD. “Lung cancer 2020: epidemiology, etiology, and prevention”. Clinics in Chest Medicine 41.1 (2020): 1-24.
  3. Bailly C, Thuru X and Quesnel B. “Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times”. NAR cancer 2.1 (2020): zcaa002.
  4. Cathcart-Rake EJ., et al. “A population-based study of immunotherapy-related toxicities in lung cancer”. Clinical lung cancer 21.5 (2020): 421-427.
  5. Chandra KC., et al. “Epidemiology of lung cancer”. Contemporary Oncology/Współczesna Onkologia 25.1 (2021): 45-52.
  6. Friedenreich M, Ryder‐Burbidge C and McNei J. “Physical activity, obesity and sedentary behavior in cancer etiology: epidemiologic evidence and biologic mechanisms”. Molecular oncology 15.3 (2021): 790-800.
  7. Gao Q., et al. “Opportunities and challenges for co-delivery nanomedicines based on combining phytochemicals with chemotherapeutic drugs in cancer treatment”. Advanced Drug Delivery Reviews (2022): 114445.
  8. Hotta AJ, Beam IA and Thomas KM. “Development of a comprehensive pediatric oncology rehabilitation program”. Pediatric Blood & Cancer 67.2 (2020): e28083.
  9. Kitts AKB. “The patient perspective on lung cancer screening and health disparities”. Journal of the American College of Radiology 16.4 (2019): 601-606.
  10. Li S., et al. “How to overcome the side effects of tumor immunotherapy”. Biomedicine & Pharmacotherapy, 130, (2020): 110639.
  11. Ligibel JA., et al. “Exercise, diet, and weight management during cancer treatment: ASCO guideline”. Journal of Clinical Oncology 40.22 (2022): 2491-2507.
  12. Lund CM., et al. “Age-related Differences in Recall of Information and Handling of Chemotherapy-related Side Effects in Cancer Patients: The ReCap Study”. The oncologist 27.2 (2022): e185-e193.
  13. Luo Q., et al. “Emerging strategies in cancer therapy combining chemotherapy with immunotherapy”. Cancer Letters 454 (2019): 191-203.
  14. Lv L., et al. “Pathogenesis, assessments, and management of chemotherapy-related cognitive impairment (CRCI): an updated literature review”. Journal of Oncology (2020).
  15. Naidoo J., et al. “A multidisciplinary toxicity team for cancer immunotherapy–related adverse events”. Journal of the National Comprehensive Cancer Network 17.6 (2019): 712-720.
  16. Naito T., et al. “Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non‐small‐cell lung cancer”. Journal of cachexia, sarcopenia, and muscle 10.1 (2019): 73-83.
  17. Ni J., et al. “Clinical recommendations for perioperative immunotherapy‐induced adverse events in non‐small cell lung cancer patients”. Thoracic Cancer 12.9 (2021): 1469-1488.
  18. Peddle‐McIntyre CJ., et al. “Exercise training for advanced lung cancer”. Cochrane Database of Systematic Reviews 2 (2019).
  19. Rahman MM., et al. “Emerging management approach for the adverse events of immunotherapy of cancer”. Molecules 27.12 (2022): 3798.
  20. Schabath MB and Cote ML. “Cancer progress and priorities: lung cancer”. Cancer epidemiology, biomarkers & prevention 28.10 (2019): 1563-1579.
  21. Schirrmacher V. “From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment”. International journal of oncology 54.2 (2019): 407-419.
  22. Sigel KM., et al. “Short-term outcomes for lung cancer resection surgery in HIV infection”. Aids 33.8 (2019): 1353-1360.
  23. Stout NL., et al. “A systematic review of rehabilitation and exercise recommendations in oncology guidelines”. CA: a cancer journal for clinicians 71.2 (2021): 149-175.
  24. Tawfik E, Ghallab E and Moustafa A. “A nurse versus a chatbot‒the effect of an empowerment program on chemotherapy-related side effects and the self-care behaviors of women living with breast cancer: a randomized controlled trial”. BMC Nursing 22.1 (2023): 102.
  25. Tuominen L., et al. “Empowering patient education on self-care activity among patients with colorectal cancer–a research protocol for a randomized trial”. BMC nursing 20.1 (2021): 94.
  26. Vaddepally R., et al. “Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)—Their Incidence, Management, Multiorgan irAEs, and Rechallenge”. Biomedicines 10.4 (2022): 790.
  27. van den Boogaard WM, Komninos DS and Vermeij WP. “Chemotherapy side-effects: not all DNA damage is equal”. Cancers 14.3 (2022): 627.
  28. Xie J, Fu L and Jin L. “Immunotherapy of gastric cancer: past, future perspective and challenges”. Pathology-Research and Practice 218 (2021): 153322.